

Pathway for Accessing Treatments for Non-Hospitalised Adults with Mild COVID-19 (Effective 10th July 2023)

Supporting Information available via [GP Gateway](#)

Patient Registered^{i,ii} with a General Practice in Coventry and Warwickshire presents to NHS Service Provider (Trust, GP, NHS 111)

All NHS Service Providers Responsible for Confirming:

1. Positive COVID-19 Lateral Flow Test
2. Symptomatic (onset within last 5 days) with COVID-19 and showing no signs of clinical recovery
3. Identified as Highest Risk (see [Independent Advisory Group Report](#))

Potentially^v Eligible^{vi}

REFER to Respiratory@Home ASAP or within 5 days of Positive test:

➤ [GP Gateway](#)

Notes:

- For patients registered with a GP outside of Coventry and Warwickshire, refer to appropriate [CMDU service](#).

Not eligible

Hospital Referral if indicated

Respiratory@Home service

1. Check referrals daily, prioritise day 3-4 window
2. Remote triage to assess [eligibility](#) and suitability using EMIS patient note
3. Follow [NICE TA 878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#) to ensure appropriate treatment choice
4. Seek specialist advice where appropriate, in this case from the R@H service Clinical Lead
5. Discuss < 18 years with responsible Specialist Paediatric Consultant/MDT where possible
6. Drug interactions via [University of Liverpool COVID-19 website](#)
7. Monitor eligible and not eligible patients and provide Respiratory@Home service where needed.

Eligible^{vi} for COVID-19 Treatment
See pg 2 overleaf

Notes:

- I. C&W residents testing positive Out of Area (OOA) should be assessed by Respiratory@Home for Paxlovid and prescription issued to the OOA [Pharmacy \(or equivalent\)](#) service.
- II. OOA patients testing positive in C&W will need to be referred to the appropriate CMDU or equivalent within their area. Temporary registration with a C&W GP will not give access to medical notes and so triage and prescription cannot happen.
- III. Clinicians requesting LFT tests for patients potentially eligible for COVID-19 treatments should clearly annotate the request with "clinical priority group".
- IV. GP Practice teams/NHS 111 are not expected to make the final decision of whether the treatment is right for a patient or prescribe any treatment, rather to refer patients that meet the policy criteria in broad terms.
- V. The final decision about eligibility rests with the Respiratory@Home clinician.
- VI. The pathway is based on available information and clinical opinion. It will be reviewed and updated, if required, as services develop, and national policy is updated.

Eligible for COVID-19 Treatments: Treatment Choice and CMDU Responsibilities

Ensure comprehensive assessment of clinical appropriateness to guide treatment choice with reference to:
[NICE TA 878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#)

Note: Please refer to the electronic versions at all times.

	1 st line	2 nd line
	PAXLOVID (SmPC) - Age 18 years & over	SOTROVIMAB (SmPC) - Aged 12 years & over
Clinical Check Requirements	Confirm exclusions including: - Pregnancy - Severe hepatic or renal impairment¹ Assessing for Paxlovid treatment Interactions with COVID-19 antiviral therapies Liverpool Drug Interactions Checker Commence treatment within 5 days of symptom onset Counsel, specifically regarding: - Pregnancy and contraception - Gastro-intestinal side effects - Completion of course, missed dose Issue PIL (Paxlovid); UKHSA leaflet; National patient website	- Paxlovid is contra-indicated or unsuitable - Confirm exclusions including: - Adolescents (aged 12 -17) weighing less than 40kg - Use in pregnancy: where expected benefit to mother justifies the risk to the foetus; liaise with appropriate specialist - Treatment is delivered within 5 days of symptom onset - Counsel - Issue PIL (Sotrovimab); National patient website
	CMDUs to contact local services for pharmacy/specialist advice as needed Prescribe treatment as appropriate:	
Advice	Paxlovid: Via NHS Community Pharmacies I. Discuss with patient: - Preferred community pharmacy considering urgency of prescription. - Standard prescription charges are applicable. - Contacting the pharmacy to confirm when the prescription is ready. - Arranging collection by an asymptomatic patient representative. II. Telephone the identified community pharmacy to: - Confirm ability to fulfil prescription before sending via EPS. - Confirm clinical checks have been completed. - Community Pharmacists are also responsible for a clinical check and may request additional information. If requested, supply (via secure nhs.net email) the completed referral form. See page 3 for further details regarding contacting community pharmacies and arrangements for urgent supply. - Advise on patient plans for medication collection. III. Complete electronic FP10 and send to selected community pharmacy: - Temporary EPS nomination may be necessary, or an EPS token provided - Include statement that it is a 'Covid Medicine Service Prescription' and telephone number for queries in FP10 'pharmacy info' section.	Sotrovimab: Via Trust Pharmacy Departments. This will be provided from the CMDUs at George Eliot Hospital and Warwick hospital. Process TBC once known
	3. Activity Reporting to ICB	
Notes	- Where a decision to prescribe is reversed, please ensure that both the provider and community pharmacy, as appropriate, are notified. - Combination treatment with an nMAB and an antiviral is NOT routinely recommended - Patients who have previously received treatment with an nMAB or antiviral, & who meet the eligibility criteria, may receive treatment for a subsequent episode, if clinically appropriate. - Where supply availability is impacting choice of treatment, consider MDT discussion to agree optimum treatment for the patients' circumstances.	

¹ See [SmPC](#) for dosing modification for moderate renal impairment.

Eligible for COVID-19 Treatments: Treatment Provision & Pharmacist Responsibilities

	PAXLOVID (SmPC) - Age 18 years & over		SOTROVIMAB (SmPC) - Aged 12 years & over
Responsibilities and Actions	Via selected Community Pharmacies: - These pharmacies are requested to keep 2 packs of Paxlovid in stock. - Respiratory@Home have been supplied with direct contact details of pharmacies.		Via Trust Pharmacy departments: Details TBC when known
Treatment provision	- Draw down prescription from the spine. - Confirm: - prescription has been generated by the triaging clinician - clinical check has been completed by prescriber - there are no outstanding concerns to preclude use of Paxlovid - Pharmacy Clinical Check and Dispensing Pharmacists are responsible for a clinical check. Additional clinical information including the completed Checklist may be requested from the prescriber, who will supply via secure nhs.net email. - Provision of Paxlovid Patient Information Leaflet (PIL), additional UKHSA Paxlovid leaflet and a pulse oximeter and further patient information (if the patient agrees with the triaging clinician to be monitored by the Respiratory@Home team). (Community pharmacies can have oximeters supplied by Respiratory@Home team). - Counsel patient in line with Paxlovid PIL, specifically regarding: - Pregnancy and contraception - Gastro-intestinal side effects - Completion of course, and missed dose - Collect standard prescription charge if applicable		Further details to be added once confirmed

Resource Signposting

- | | |
|--|--|
| 1. In addition to resources on pages 1 and 2 of this document, a complete list of resources are available via Liverpool COVID-19 Interactions (covid19-druginteractions.org) including: | |
| <ul style="list-style-type: none"> Guidance for resuming paused or dose-adjusted comedications with Paxlovid Swallowing Difficulties - Administering Paxlovid as Crushed Tablets Guidance for Paxlovid dosing in patients with renal disease and patients on dialysis | <ul style="list-style-type: none"> COVID-19 Therapies – Dose Recommendations for Patients with Renal Impairment COVID-19 Therapies - Dose Recommendations for Patients with Hepatic Impairment |
| 2. COVID-19 Antivirals – Community Pharmacy Coventry and Warwickshire | |
| 3. Specialist Pharmacy Service Medicines Advice contact details: telephone 0300 770 8564 or email: asksp.s.nhs@sps.direct | |
| 4. E-Learning training materials: COVID-19 Treatments is available here (Registration on NHS Learning Hub is required) | |
| 5. PAXLOVID ▼ (nirmatrelvir/ritonavir) - PfizerPro UK | |
| 6. Key Opinion Leader videos including: managing drug-drug interactions, importance of managing COVID, identifying & educating high risk patients | |
| 7. Specialist Pharmacy Service: Accessing COVID-19 Medicines Advice for Primary Care | |